Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 57 Publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NHza[plHfW6ldHnvckBCe3OjeR?= MWOwMlXDqM7:TR?= NUjwRlBrOjRiaB?= MWT3ZZRmeg>? NWTxZYlwdW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? NH;tcVQzPTF{M{C4Ni=>
Eca109 NX;SRWRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCwMlUwOi53L{Wg{txO M3vUO|I1NzR6L{eyJIg> MX\3ZZRmeg>? MofabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= MW[yOVEzOzB6Mh?=
Eca109 M{XVXGZ2dmO2aX;uJGF{e2G7 NWfXV3BROC53wrFOwG0> NIrqOok3NzF{L{K0JIg> M2jONpdifGW{ MULpcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi NXvvXph1OjVzMkOwPFI>
Eca109 M4rtNWZ2dmO2aX;uJGF{e2G7 NXvCeHpWOC53wrFOwG0> M{HlOFI1KGh? MUT3ZZRmeg>? NH23cIdqdmirYnn0d{Bk\WyuIHnueoF{cW:w MnO4NlUyOjNyOEK=
Eca109 M2PkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD1NE42yqEQvF2= M3;HdlI1KGh? NFjKOpF4[XSnch?= M3rQOYlv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> MnG5NlUyOjNyOEK=
Eca109 M3fme2Z2dmO2aX;uJGF{e2G7 Ml3hNE42NzFizszN MnrNNlQhcA>? MXf3ZZRmeg>? MoS5[IVkemWjc3XzJIV5eHKnc4Ppc44hd2ZiTl[t{tpDOiCjbnSgUW1ROg>? MXOyOVEzOzB6Mh?=
SW1116  MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jWcVAvPS9zL{KvOUDPxE1? NX3IdXdIPDhiaB?= NGLVWHBFVVOR NEfHboVmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v NWHmRnp[OjR6N{SyPFY>
LOVO NGry[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{flb|AvPS9zL{KvOUDPxE1? MXW0PEBp NYnvd5hNTE2VTx?= Ml;l[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> MWeyOFg4PDJ6Nh?=
SW1116  MY\GeY5kfGmxbjDBd5NigQ>? M2WzWVExKM7:TR?= MWm0PEBp MkLCSG1UVw>? Mme0bY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MViyOFg4PDJ6Nh?=
LOVO NYDEWJN[TnWwY4Tpc44hSXO|YYm= MVexNEDPxE1? NWSzfJZSPDhiaB?= MWLEUXNQ NXj5OoVHcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk M4GwRlI1QDd2Mki2
SW1116  Ml[1RZBweHSxc3nzJGF{e2G7 NF\lbIIyOCEQvF2= M3S5WlQ5KGh? NWe2O4k4TE2VTx?= MoS3[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MWeyOFg4PDJ6Nh?=
LOVO Mk\zRZBweHSxc3nzJGF{e2G7 NEWyZWsyOCEQvF2= MoPJOFghcA>? M1vJVmROW09? NX36eJNy\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MVmyOFg4PDJ6Nh?=
RPMI-8226 MmPMRZBweHSxc3nzJGF{e2G7 MX6xM|Ih|ryP MVS0PE84Oi97NjDo MUnEUXNQ MoS4bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M4HQWVI1QDN|MUC4
OPM-2  Ml7vRZBweHSxc3nzJGF{e2G7 MVOxM|Ih|ryP M2fTXVczNzl4L{GyNEBp M1vV[WROW09? Mn[1bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MnXRNlQ5OzNzMEi=
JJN3  M17OTmFxd3C2b4Ppd{BCe3OjeR?= MlXqNE42NzFizszN NFO4SmczPC92ODDo NWPoV415TE2VTx?= M1TRd4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Mk\UNlQ5OzNzMEi=
NCI-H929  NGTydGdCeG:ydH;zbZMhSXO|YYm= MoXkNU8zKM7:TR?= NV3ZRZhCPzJxOU[vNVIxKGh? NWjqV2dLTE2VTx?= M1TJTolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2jpUVI1QDN|MUC4
RPMI-8226 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\jfmgyNzJizszN MVqyOE81QC95MjDo M4DBTmROW09? M3TWbIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 M{izcVI1QDN|MUC4
OPM-2  NX\tOIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPLNU8zKM7:TR?= MUmyOE81QC95MjDo M1vMSWROW09? MVPh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NX7TOJY5OjR6M{OxNFg>
JJN3  M{XuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmwMlUwOSEQvF2= MVOyOE81QC95MjDo MUXEUXNQ MnizZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? M3K0eFI1QDN|MUC4
NCI-H929  NUDNR4xGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWexM|Ih|ryP MXOyOE81QC95MjDo Mk\0SG1UVw>? NICzRZhi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MmK3NlQ5OzNzMEi=
HeLa M1rkS2tqdmG|ZTDBd5NigQ>? M4Dy[mtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE> M4KxWFI1PzhyMEm4
HeLa M1fVS2tqdmG|ZTDBd5NigQ>? MXjLbV02NjZiwsGgNE42KM7:TTDmc5IhcEWQVEK= NUDvc5JROjR5OECwPVg>
HeLa NITZdVBMcW6jc3WgRZN{[Xl? MmjJT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> MlrrNlQ4QDByOUi=
HeLa NHyze4dMcW6jc3WgRZN{[Xl? NXfJOnNKU2l;MUSuOEDDuSB2Lk[g{txOKG[xcjDoR25VOw>? NYL0cYhCOjR5OECwPVg>
NB4 M3\KOGZ2dmO2aX;uJGF{e2G7 M1zyfVIvPS93L{euOU8yOCEQvF2= MYKyOEBp Mo\BSG1UVw>? M2LHZ4lv[3KnYYPlZUB1cGViZYjwdoV{e2mxbjDv[kBxemWldYLzc5IhdWmULUGyOYE> M1u4S|I1PDh2OEew
CD4+ CD25− T  NH\wcmJHfW6ldHnvckBCe3OjeR?= M3fSW|EwPSEQvF2= NV74SGJ3emWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w MnHENlQ1PzZ|NkC=
BV-173 NFPtNoZCeG:ydH;zbZMhSXO|YYm= NWXscWhXOC5{NT:wMlUwOC55NT:xJO69VQ>? NHXYWnI1QC95Mj:5OkBp NX\jcXAzyqCSQmO= NX\6S4JvcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NXy5SG9FOjR2MkO2NVM>
ML-1 NHntRnpCeG:ydH;zbZMhSXO|YYm= NFnMZ2YxNjJ3L{CuOU8xNjd3L{Gg{txO NU\zWXNmPDhxN{KvPVYhcA>? MVdCpHBDWw>? NFfLVJBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MYqyOFQzOzZzMx?=
HL-60 MWjBdI9xfG:|aYOgRZN{[Xl? NIL2e4gxNjJ3L{CuOU8xNjd3L{Gg{txO NYHPdI1KPDhxN{KvPVYhcA>? NFjUV|nDqFCEUx?= NYfyU|dqcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MWKyOFQzOzZzMx?=
KG-1a MkfZRZBweHSxc3nzJGF{e2G7 MUOwMlI2NzBwNT:wMlc2NzFizszN NUDCRWNDPDhxN{KvPVYhcA>? MkfLxsBRSlN? MlXObY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MkDrNlQ1OjN4MUO=
BV-173 NF;NV4VHfW6ldHnvckBCe3OjeR?= M4\2e|I2OC93MEDuUS=> NXn1So1TPDhiaB?= NV\BfoZJyqCSQmO= NVewSoN[cW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NGLhT5UzPDR{M{[xNy=>
CEM NYDXR3F[TnWwY4Tpc44hSXO|YYm= MYeyOVAwPTBybl2= NWe4R4dbPDhiaB?= MXpCpHBDWw>? NITkUItqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NHry[nozPDR{M{[xNy=>
HL-60 MlvnSpVv[3Srb36gRZN{[Xl? MV2yOVAwPTBybl2= NFfDc4s1QCCq NXrYfGREyqCSQmO= MVPpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NWrt[|VnOjR2MkO2NVM>
ML-1 MYTGeY5kfGmxbjDBd5NigQ>? NHXHSWUzPTBxNUCwcm0> MYi0PEBp NULtXGc1yqCSQmO= NFvhUIhqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M1HQUFI1PDJ|NkGz
DLD-1 MnLtSpVv[3Srb36gRZN{[Xl? NF3XU2YzPTBxNUCwcm0> NF7tbmw1QCCq NX;Oc2NvyqCSQmO= NFfwXoJldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M33NblI1PDJ|NkGz
HCT-116 NH;iZ21HfW6ldHnvckBCe3OjeR?= M2PKclI2OC93MEDuUS=> MmTQOFghcA>? M2G1[:KhWEKV NVPKT|BJ\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NFvxWnkzPDR{M{[xNy=>
U937-A/E-9/14/18  MoLSRZBweHSxc3nzJGF{e2G7 M33DVlAvODFxMD6xM|EwOTBizszN MXi0PEBp NUPpb4xCcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWLhbZVkOjR|MEC0OVY>
HT29 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3RZXN1PzJiaB?= NHLLeodKSzVyPUG0NFDDuTF5OTFOwG0> NFfXXoczPDF5MkC2NS=>
SW48 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX23NkBp NETJOllKSzVyPUG1MlLDuTZwMjFOwG0> NYDtbY9EOjRzN{KwOlE>
HCT116 Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfhZZp4PzJiaB?= NG[xSFJKSzVyPUGuO:KyOC52IN88US=> NUH6e4VlOjRzN{KwOlE>
HepG2 M2DJcmZ2dmO2aX;uJGF{e2G7 M1z2WlAvPS9zIN88US=> MkTUNlQhcA>? NWW5OVNnTE2VTx?= MlP2eZAuemWpdXzheIVlKHSqZTDy[YxifGm4ZTDPR3RPOiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? MXmyOFE1Pjh5NB?=
LS174T M3v0SGZ2dmO2aX;uJGF{e2G7 NYnseGhnOC53L{Gg{txO MnLiNlQhcA>? M1fQWmROW09? NVLUTnZFdGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> Mn\GNlQyPDZ6N{S=
HepG2 M2fBOWFxd3C2b4Ppd{BCe3OjeR?= Mn[4NU8yOC9zMECg{txO NY\5cppLPyCm Mk\RSG1UVw>? Ml[wbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVnNTVJ1OjRzNE[4O|Q>
LS174T NImxdFNCeG:ydH;zbZMhSXO|YYm= NITMboYyNzFyL{GwNEDPxE1? M13melch\A>? MWPEUXNQ NXfoe5pCcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYPLeWltOjRzNE[4O|Q>
QBC-939 Mo[wRZBweHSxc3nzJGF{e2G7 MlK1NU8yOC9zMECg{txO MWO3JIQ> MX;EUXNQ MnPSbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1T4ZVI1OTR4OEe0
U251 MXLBdI9xfG:|aYOgRZN{[Xl? NVPlNWhKOS9zMD:xNFAh|ryP M1f5S|ch\A>? NH7aXmdFVVOR NEfPR5dqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{HTc|I1OTR4OEe0
HL-60 MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDyU2cyKM7:TR?= NXLiZmREPDhiaB?= NEXEe4RqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?= MmfBNlQxODB|MkS=
MDA‑MB‑453 NFiyXYRHfW6ldHnvckBCe3OjeR?= MYqwMlIwOSEQvF2= NIe2T5Y4OiCq NILiXW1k[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NYPxUFVpOjN6NESyNlg>
HCC1569 MUXGeY5kfGmxbjDBd5NigQ>? NWrneJZMOC5{L{Gg{txO NWj5eJR5PzJiaB?= NEO3PHRk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MWmyN|g1PDJ{OB?=
BT‑474 NU[3fGpCTnWwY4Tpc44hSXO|YYm= NUnSRWVYOC5{L{Gg{txO MX23NkBp MWHjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NFvkNFUzOzh2NEKyPC=>
AGS M3uxOmFxd3C2b4Ppd{BCe3OjeR?= M4XOUVUwOTBxMkCvOVAh|ryP MlL3OFjDqGkEoB?= MXvEUXNQ MUTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NEjKZWozOzV6Mke4OC=>
A549 MmGxRZBweHSxc3nzJGF{e2G7 MXG1M|ExNzJyL{WwJO69VQ>? NEO0T4Y1QMLiaNMg NFX6PG1FVVOR M{DGXolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh MVGyN|U5Ojd6NB?=
AGS  NG\v[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP0U3B4PS9zMD:yNE82OCEQvF2= MofwOFjDqGkEoB?= MmDWSG1UVw>? MlfwbY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg NXv2N4NLOjN3OEK3PFQ>
Kasumi-1 MXvBdI9xfG:|aYOgRZN{[Xl? MWKwMlUh|ryP MXG0POKhcMLi MoPT[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= M3TucVI{PDl|M{S4
OCI-AML3 Moq3RZBweHSxc3nzJGF{e2G7 MV[yMlUh|ryP NHr3N4w1QMLiaNMg M1LaUYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NUHIcJBrOjN2OUOzOFg>
MV4-11 NWTtSo1USXCxcITvd4l{KEG|c3H5 M3TTflIvPSEQvF2= NVLqOmJFPDkEoHlCpC=> Mn3F[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= MlT5NlM1QTN|NEi=
NK  NUjqRY1TS3m2b4TvfIl1gSCDc4PhfS=> MXGwMlAzNTJyIN88US=> NEH1[FA2KGR? MUPk[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm NIPIT2wzOzN{OEC4PC=>
NK  MVTBdI9xfG:|aYOgRZN{[Xl? NVr2XZd2OC5yMj2yNEDPxE1? NWLDeWFvPSCm Mn[z[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl MWKyN|MzQDB6OB?=
NK  M2jhN2Z2dmO2aX;uJGF{e2G7 MWmwMlAyNTJyIN88US=> MXW1JIQ> M3nMcYNifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> NXLhfZdjOjN|MkiwPFg>
MOLT4/DNR NX;yVW1jTnWwY4Tpc44hSXO|YYm= MljNOUDPxE1? Mlv4OEBl MXny[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> NWfmU4VZOjNyNkC1O|A>
Jurkat/DOX MXjGeY5kfGmxbjDBd5NigQ>? M3P0d|Uh|ryP NVmzcHFxPCCm MkfrdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> NGS2VYQzOzB4MEW3NC=>
MOLT4/DNR NU\VeFNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC1JO69VQ>? MUK0JIQ> NV;GUm1IemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> NUfhfYZuOjNyNkC1O|A>
Jurkat/DOX M2HVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUS1JO69VQ>? M3zFZVQh\A>? NFflPIVz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 M4TTOFI{ODZyNUew
ccRCC  M2S1XWFxd3C2b4Ppd{BCe3OjeR?= M1W3fVAvODFvMUFOwG0> M{m5cFczKGh? M1;YbWROW09? MVzoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v MUSyNlgzPjR4Nx?=
TNBC  MXPBdI9xfG:|aYOgRZN{[Xl? NWX6d45OOC5yMT2xNO69VQ>? MX[3NkBp M{fWRmROW09? NYPJdFZucGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= NHXJ[VQzOjh{NkS2Oy=>
A498 NXz6W|hmSXCxcITvd4l{KEG|c3H5 MnLaNE4xOS1zMN88US=> NUnTOY9zPzJiaB?= M2DlfGROW09? MWfpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MVeyNlgzPjR4Nx?=
KIJ265T NHTFUldCeG:ydH;zbZMhSXO|YYm= M37OWFAvODFvMUFOwG0> M4D6PVczKGh? NWPtXoU3TE2VTx?= NGnFb5ZqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NGfyVpEzOjh{NkS2Oy=>
MDA-231 MWPBdI9xfG:|aYOgRZN{[Xl? NYHi[JRFOC5yMT2xNO69VQ>? M3z5SVczKGh? NGe5U2FFVVOR MUPpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NUG1[5J[OjJ6Mk[0Olc>
BT-20 NXywTmdiSXCxcITvd4l{KEG|c3H5 NWLXeJJHOC5yMT2xNO69VQ>? MnGzO|IhcA>? Ml3DSG1UVw>? NGLTTpJqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NYDxfmduOjJ6Mk[0Olc>
U937 NX7iUG1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrMbW83PS1{MDFOwG0> NUPZOlBlOjRxNEivO|IhcA>? NWPGOYJHcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M335NlIzPzZ5MEKx
HL60 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XnUlUuOjBizszN MnztNlQwPDhxN{KgbC=> NVPX[Y92cW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MmXZNlI4PjdyMkG=
U937 NGPvUY1CeG:ydH;zbZMhSXO|YYm= NFXXT5EyPSEQvF2= NWfGOnlKOjRxNEivO|IhcA>? NVTPco1ocW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NFPzXlMzOjd4N{CyNS=>
HL60 MlviRZBweHSxc3nzJGF{e2G7 MXWxOUDPxE1? M1vsNVI1NzR6L{eyJIg> NU\HWmhycW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= Mn;PNlI4PjdyMkG=
LS411N  MWjBdI9xfG:|aYOgRZN{[Xl? MWGwMlUh|ryP NUf5OIloPzJiaB?= NGDscWNqdmO{ZXHz[ZMhTmG|IH3SUmEhdGW4ZXy= NYT6UFVTOjJ2NkG2PVU>
MDA-MB-231 M1TUUGFxd3C2b4Ppd{BCe3OjeR?= NWPySGgyOTBizszN MUS0PEBp NELzRo9z\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MofJNlE5QDd4OUe=
MCF-7  MmLmRZBweHSxc3nzJGF{e2G7 NFHjZnQyOCEQvF2= Mn33OFghcA>? M12yUZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{LEb|IyQDh5Nkm3
A375 MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XXdlAvPSEQvF2= MWCxM|UwQCCm NXrDWol5cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NV\oPVRXOjF5OU[2NlI>
SKMEL1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGwMlUh|ryP NYTwT|RsOS93L{ig[C=> NWLaeohucW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NHnRepAzOTd7Nk[yNi=>
SKMEL3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj5e|JEOC53IN88US=> NF60epUyNzVxODDk NXKzfGlScW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MmrzNlE4QTZ4MkK=
SKMEL28 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWewMlUh|ryP NUTVfnJGOS93L{ig[C=> NVLU[HFUcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M2PuTVIyPzl4NkKy
MeWo NWHuWpU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnTNE42KM7:TR?= M4racFEwPS96IHS= MnLybY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NWfwO|RYOjF5OU[2NlI>
B16 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG1SnpJOC53IN88US=> NYDxdW1{OS93L{ig[C=> NYHWV|hRcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MlnlNlE4QTZ4MkK=
Ly 1 M4jsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGyOEBp MWnJR|UxRTdwMzFOwG0> MnPZNlE4PzJyNEm=
Ly 7 NXLPdGVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\wclI1KGh? NGr5b5RKSzVyPUGwMlch|ryP NHjCe2EzOTd5MkC0PS=>
Su-DHL6 NFm3NZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLEZoYzPCCq MnW0TWM2OO,:nkKwJO69VQ>? MViyNVc4OjB2OR?=
Ly 10 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETPXmszPCCq NVjmVXpkUUN3MP-8olIxKM7:TR?= MUSyNVc4OjB2OR?=
RIVA M2PnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fGelI1KGh? NV3SV5lrUUN3MP-8olIxKM7:TR?= MYiyNVc4OjB2OR?=
Su-DHL2 M1[wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVeyOEBp M2LYcWlEPTExvK6yNEDPxE1? M1vkXlIyPzd{MES5
Ly 1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjpc241QCCq NYrRZpJsUUN3ME2wMlM1KM7:TR?= NX\BWYQ2OjF5N{KwOFk>
Ly 7 MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fTTVQ5KGh? MV3JR|UxRTBwMEK1JO69VQ>? MmruNlE4PzJyNEm=
Su-DHL6 NELFW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3WeYxJPDhiaB?= MWLJR|Ux97zgMkCg{txO NX;DU4s2OjF5N{KwOFk>
Ly 10 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonFOFghcA>? MlfaTWM2OD1zLkig{txO MWSyNVc4OjB2OR?=
RIVA NXHBbYdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTjOFghcA>? MnHBTWM2OO,:nkKwJO69VQ>? M3\qXFIyPzd{MES5
Su-DHL2 M1fK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fPTFQ5KGh? NEnBU2VKSzVyPUG3MlQh|ryP MlnONlE4PzJyNEm=
Ly 1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO3NkBp NE\UN5FKSzVyPUCuNFEh|ryP NFvySVYzOTd5MkC0PS=>
Ly 7 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\NSpg4OiCq MYDJR|UxRTBwMEG4JO69VQ>? NXTBeFVsOjF5N{KwOFk>
Su-DHL6 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\EVlc3PzJiaB?= Mn;NTWM2OD1zLk[g{txO NH2wNG0zOTd5MkC0PS=>
Ly 10 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6zO|IhcA>? NXHxVlFYUUN3ME2xMlIh|ryP MkHONlE4PzJyNEm=
RIVA M3Xpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\hfXp4PzJiaB?= MnXPTWM2OO,:nkKwJO69VQ>? NUPjZ3lGOjF5N{KwOFk>
Su-DHL2 NU\MSFJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT2UYo4OiCq MoDITWM2OD1zMT6yJO69VQ>? NXrQT2xEOjF5N{KwOFk>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
- Collapse

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
- Collapse
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04086238 Recruiting Drug: Decitabine Healthy EpiDestiny Inc. October 9 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03828084 Completed Drug: Decitabine Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03875287 Recruiting Drug: Decitabine|Drug: Cedazuridine Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals April 17 2019 Phase 1
NCT03593915 Recruiting Combination Product: Alvocidib Plus Decitabine Myelodysplastic Syndromes (MDS) Tolero Pharmaceuticals Inc. August 29 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID